Bausch + Lomb Corporation $BLCO Shares Sold by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd reduced its stake in Bausch + Lomb Corporation by 48% in Q1, selling 23,145 shares and now holding 25,083 shares valued at approximately $364,000.
• During the latest earnings report, Bausch + Lomb reported a 0.07 EPS, exceeding analysts' expectations, with revenue of $1.28 billion for the quarter.
• Institutional investors' ownership of Bausch + Lomb is at 11.07%, with varying ratings from analysts, resulting in a consensus target price of $15.56.

Dynamic Technology Lab Private Ltd trimmed its holdings in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) by 48.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,083 shares of the company's stock after selling 23,145 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Bausch + Lomb were worth $364,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in BLCO. Deutsche Bank AG purchased a new position in shares of Bausch + Lomb in the first quarter valued at about $50,750,000. Allianz Asset Management GmbH purchased a new position in shares of Bausch + Lomb in the first quarter valued at about $4,712,000. Alberta Investment Management Corp lifted its position in shares of Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company's stock valued at $47,360,000 after acquiring an additional 258,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Bausch + Lomb in the first quarter valued at about $2,119,000. Finally, Tang Capital Management LLC lifted its position in shares of Bausch + Lomb by 28.6% in the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company's stock valued at $8,127,000 after acquiring an additional 100,000 shares in the last quarter. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Trading Up 1.9%

BLCO traded up $0.28 during trading on Wednesday, hitting $15.18. 24,286 shares of the stock were exchanged, compared to its average volume of 757,825. The firm has a 50 day simple moving average of $14.37 and a 200 day simple moving average of $13.41. The firm has a market cap of $5.37 billion, a price-to-earnings ratio of -19.46, a P/E/G ratio of 1.55 and a beta of 0.63. Bausch + Lomb Corporation has a 1 year low of $10.45 and a 1 year high of $21.69. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.Bausch + Lomb's quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BLCO shares. Zacks Research raised Bausch + Lomb to a "hold" rating in a report on Tuesday, August 12th. Wells Fargo & Company lifted their target price on Bausch + Lomb from $12.00 to $15.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Evercore ISI lifted their target price on Bausch + Lomb from $15.50 to $16.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Morgan Stanley lifted their target price on Bausch + Lomb from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Finally, Citigroup boosted their price objective on Bausch + Lomb from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $15.56.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.